Vaginal epithelium and mucosa

The vaginal epithelium and mucosal surface structures represent the primary physical and immunological barrier of the female lower reproductive tract (StatPearls, 2023). This non-keratinized stratified squamous epithelium is coated with a protective mucus layer composed of mucins, antibodies, and antimicrobial peptides (PubMed, 2014). In the context of pharmacology, these structures are the site of action for topical microbicides, lubricants, and hormonal therapies, and they serve as a portal for systemic drug absorption (NIH, 2005). The health of this mucosal surface is maintained by a low pH environment and a dominant population of Lactobacillus species, which inhibit the growth of pathogenic organisms (Frontiers in Microbiology, 2021). Disruption of this barrier, whether through chemical irritation or physical trauma, can significantly increase the risk of acquiring sexually transmitted infections such as HIV (The Lancet Infectious Diseases, 2013). Consequently, drug development targeting this area must balance efficacy with the preservation of mucosal integrity and the local microbiome (Journal of Controlled Release, 2016). The epithelium also undergoes cyclic changes in thickness and glycogen content under the influence of estrogen, affecting its barrier properties (Mayo Clinic, 2023). Understanding the interaction between drugs and these mucosal structures is essential for designing safe and effective intravaginal therapies (Journal of Controlled Release, 2016).

Other names

Vaginal mucosaVaginal epithelial surfaceVaginal liningVaginal wallCervicovaginal mucosa

Drugs interact with these structures through topical application, where they may form a physical barrier, modulate the local pH, or be absorbed through the epithelium into the systemic circulation (NIH, 2005; Journal of Controlled Release, 2016).